2025-04-08
1. Summary of the Week
From April 1 to 6, a total of nine licensing and cooperation deals were signed globally. In the China biotech industry, there was one in-licensing deal and one domestic deal.
Antelope Surgical Solutions and Primo Biotechnology signed a cooperation agreement for AS1986NS, while XtalPiand Pacific ShuanglinBio-Pharmacy entered into a cooperation deal in blood products, with a total deal value of $13.9 million.
Globally, seven agreements were announced. The top deal of the week was the licensing agreement between Sangamo Therapeutics and Eli Lilly for the STAC-BBB capsid, with a total deal value of $1.418 billion and an upfront payment of $18 million.
2025年4月1-6日，全球医药市场共签署了9项资产授权和合作协议。中国市场共达成2项交易，包括1项引进交易和1项国内交易。
引进交易方面，普瑞默生技与Antelope Surgical Solutions就AS1986NS开展临床合作。国内交易方面，晶泰科技与派林生物在血液制品领域达成战略合作，总价值1390万美元。
国际市场上，本周共签署了7项资产授权和合作协议。最大的一笔交易是Eli Lilly与Sangamo Therapeutics就STAC-BBB衣壳达成的许可协议，首付款1800万美元，总金额14.18亿美元。
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of 2025
5. 2019-2024 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
ACCESS CHINA
Event Name:
2025-06 ACCESS CHINA @ Boston Forum, Boston
BioToChina.org 